Evidence map›Paper›PMID 23974095›Full record

ArticleCell cycle (Georgetown, Tex.)2013

Nuclear reprogramming of luminal-like breast cancer cells generates Sox2-overexpressing cancer stem-like cellular states harboring transcriptional activation of the mTOR pathway.

Bruna Corominas-Faja, Sílvia Cufí, Cristina Oliveras-Ferraros, Elisabet Cuyàs, Eugeni López-Bonet, Ruth Lupu, Tomás Alarcón, Luciano Vellon, Juan Manuel Iglesias, Olatz Leis and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.

0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

73 citing papers in PubMed, 105 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Cancer Cell Culture: The Basics and Two-Dimensional Cultures.Methods in molecular biology (Clifton, N.J.) · 2023
    Article
  11. Review
  12. Article
  13. Review
  14. CRISPR-Cas technology a new era in genomic engineering.Biotechnology reports (Amsterdam, Netherlands) · 2022
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

13 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 4 countries.

Bruna Corominas-FajaMetabolism & Cancer Group; Translational Research Laboratory; Catalan Institute of Oncology-Girona (ICO-Girona); Girona, Spain; Molecular Oncology; Girona Biomedical Research Institute (IDIBGI); Girona, Spain.
Sílvia Cufí
Cristina Oliveras-Ferraros
Elisabet Cuyàs
Eugeni López-Bonet
Ruth Lupu
Tomás Alarcón
Luciano Vellon
Juan Manuel Iglesias
Olatz Leis
Ángel G Martín
Alejandro Vazquez-Martin
Javier A Menendez
Institute of Molecular and Cell Biology · RUMolecular Oncology (United States) · USCatalan Institute for Water Research · ESCentre de Recerca Matemàtica · ESDiputación Foral de Gipuzkoa · ESHospital Universitari de Girona Doctor Josep Trueta · ESInstitut Català d'Oncologia · ESInstitut d'Investigació Biomèdica de Girona · ESMatia Fundazioa · ESMayo Clinic · USTranslational Research Institute · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Energy metabolism plasticity enables stemness programs during the reprogramming of somatic cells to an induced pluripotent stem cell (iPSC) state. This relationship may introduce a new era in the understanding of Warburg's theory on the metabolic origin of cancer at the level of cancer stem cells (CSCs). Here, we used Yamanaka's stem cell technology in an attempt to create stable CSC research lines in which to dissect the transcriptional control of mTOR--the master switch of cellular catabolism and anabolism--in CSC-like states. The rare colonies with iPSC-like morphology, obtained following the viral transduction of the Oct4, Sox2, Klf4, and c-Myc (OSKM) stemness factors into MCF-7 luminal-like breast cancer cells (MCF-7/Rep), demonstrated an intermediate state between cancer cells and bona fide iPSCs. MCF-7/Rep cells notably overexpressed SOX2 and stage-specific embryonic antigen (SSEA)-4 proteins; however, other stemness-related markers (OCT4, NANOG, SSEA-1, TRA-1-60, and TRA-1-81) were found at low to moderate levels. The transcriptional analyses of OSKM factors confirmed the strong but unique reactivation of the endogenous Sox2 stemness gene accompanied by the silencing of the exogenous Sox2 transgene in MCF-7/Rep cells. Some but not all MCF-7/Rep cells acquired strong alkaline phosphatase (AP) activity compared with MCF-7 parental cells. SOX2-overexpressing MCF-7/Rep cells contained drastically higher percentages of CD44(+) and ALDEFLUOR-stained ALDH(bright) cells than MCF-7 parental cells. The overlap between differentially expressed mTOR signaling-related genes in 3 different SOX2-overexpressing CSC-like cell lines revealed a notable downregulation of 3 genes, PRKAA1 (which codes for the catalytic α 1 subunit of AMPK), DDIT4/REDD1 (a stress response gene that operates as a negative regulator of mTOR), and DEPTOR (a naturally occurring endogenous inhibitor of mTOR activity). The insulin-receptor gene (INSR) was differentially upregulated in MCF-7/Rep cells. Consistent with the downregulation of AMPK expression, immunoblotting procedures confirmed upregulation of p70S6K and increased phosphorylation of mTOR in Sox2-overexpressing CSC-like cell populations. Using an in vitro model of the de novo generation of CSC-like states through the nuclear reprogramming of an established breast cancer cell line, we reveal that the transcriptional suppression of mTOR repressors is an intrinsic process occurring during the acquisition of CSC-like properties by differentiated populations of luminal-like breast cancer cells. This approach may provide a new path for obtaining information about preventing the appearance of CSCs through the modulation of the AMPK/mTOR pathway.

Indexed as

Cellular ReprogrammingAMP-Activated Protein KinasesBreast NeoplasmsDown-RegulationFatty Acid Synthase, Type IFemaleHumansIntracellular Signaling Peptides and ProteinsKinesinsKruppel-Like Factor 4MCF-7 CellsNeoplastic Stem CellsOctamer Transcription Factor-3PhosphorylationProto-Oncogene Proteins c-mycReceptor, InsulinAMP-Activated Protein KinasesDDIT4 protein, humanDEPTOR protein, humanFASN protein, humanFatty Acid Synthase, Type IIntracellular Signaling Peptides and ProteinsKIF4A protein, humanKinesinsKLF4 protein, humanKruppel-Like Factor 4MTOR protein, humanOctamer Transcription Factor-3PRKAA1 protein, humanProto-Oncogene Proteins c-mycReceptor, InsulinRibosomal Protein S6 Kinases, 70-kDaRNA, Small InterferingSOX2 protein, humanSOXB1 Transcription FactorsTOR Serine-Threonine KinasesTranscription FactorsAMPKbreast cancercancer stem cellsmTORreprogrammingSOX2

Identifiers

PMID23974095
PMCPMC3875684
OpenAlexW2148310630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.